Is the restricted ketogenic diet a viable alternative to the standard of care for managing malignant brain cancer?

Epilepsy Research

Volumn 100, Issue 3, 2012, Pages 310-326

  Seyfried, Thomas N ^a   Marsh, Jeremy ^a,b   Shelton, Laura M ^a,c   Huysentruyt, Leanne C ^a,d   Mukherjee, Purna ^a  

^a BOSTON COLLEGE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c Minerva Biotechnologies   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Calorie restriction; Energy metabolism; Glioblastoma

Indexed keywords

DEOXYGLUCOSE; GLUCOSE; GLUTAMINE; HYPOXIA INDUCIBLE FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN C;

AMINO ACID METABOLISM; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; ASTROCYTOMA; BRAIN CANCER; CALORIC INTAKE; CALORIC RESTRICTION; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CELL METABOLISM; CLINICAL EFFECTIVENESS; CONCENTRATION (PARAMETERS); DISEASE MODEL; DRUG MEGADOSE; ENERGY METABOLISM; EPILEPSY; GLIOBLASTOMA; GLIOMA; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPOGLYCEMIA; KETOGENIC DIET; LETHARGY; LOW DRUG DOSE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROTEIN TARGETING; RESTRICTED KETOGENIC DIET; SIDE EFFECT; TUMOR CELL; TUMOR VASCULARIZATION; WEIGHT REDUCTION;

ANIMALS; BRAIN NEOPLASMS; CALORIC RESTRICTION; ENERGY METABOLISM; GLIOBLASTOMA; GLUCOSE; HUMANS; KETOGENIC DIET;

EID: 84862211488     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2011.06.017     Document Type: Article

References (175)

1. Aft R.L., Zhang F.W., Gius D. Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death. Br. J. Cancer 2002, 87:805-812.
2. Aller S.G., Yu J., Ward A., Weng Y., Chittaboina S., Zhuo R., Harrell P.M., Trinh Y.T., Zhang Q., Urbatsch I.L., Chang G. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009, 323:1718-1722.
3. Arismendi-Morillo G. Electron microscopy morphology of the mitochondrial network in human cancer. Int. J. Biochem. Cell Biol. 2009, 41:2062-2068.
4. Arismendi-Morillo G. Electron microscopy morphology of the mitochondrial network in gliomas and their vascular microenvironment. Biochim. Biophys. Acta 2010, 57:33-39.
5. Arismendi-Morillo G.J., Castellano-Ramirez A.V. Ultrastructural mitochondrial pathology in human astrocytic tumors: potentials implications pro-therapeutics strategies. J. Electron Microsc. (Tokyo) 2008, 57:33-39.
6. Atkinson G.P., Nozell S.E., Harrison D.K., Stonecypher M.S., Chen D., Benveniste E.N. The prolyl isomerase Pin1 regulates the NF-kappaB signaling pathway and interleukin-8 expression in glioblastoma. Oncogene 2009, 28:3735-3745.
7. Badie B., Schartner J.M., Hagar A.R., Prabakaran S., Peebles T.R., Bartley B., Lapsiwala S., Resnick D.K., Vorpahl J. Microglia cyclooxygenase-2 activity in experimental gliomas: possible role in cerebral edema formation. Clin. Cancer Res. 2003, 9:872-877.
8. Bayley J.P., Devilee P. Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree?. Curr. Opin. Genet. Dev. 2010, 20:324-329.
9. Cabioglu N., Sahin A., Doucet M., Yavuz E., Igci A., Aktas E.O.Y., Bilgic E., Kiran S., Deniz B., Price G.J.E. Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow. Clin. Exp. Metastasis 2005, 22:39-46.
10. Cahill G.F., Veech R.L. Ketoacids? Good medicine?. Trans. Am. Clin. Climatol. Assoc. 2003, 114:149-161. discussion 162-143.
11. Carew J.S., Huang P. Mitochondrial defects in cancer. Mol. Cancer 2002, 1:9.
12. Cay O., Radnell M., Jeppsson B., Ahren B., Bengmark S. Inhibitory effect of 2-deoxy-D-glucose on liver tumor growth in rats. Cancer Res. 1992, 52:5794-5796.
13. Chandra D., Singh K.K. Genetic insights into OXPHOS defect and its role in cancer. Biochim. Biophys. Acta 2010, 1807:620-625.
14. Chang S.M., Parney I.F., Huang W., Anderson F.A., Asher A.L., Bernstein M., Lillehei K.O., Brem H., Berger M.S., Laws E.R. Patterns of care for adults with newly diagnosed malignant glioma. JAMA 2005, 293:557-564.
15. Chen R., Nishimura M.C., Bumbaca S.M., Kharbanda S., Forrest W.F., Kasman I.M., Greve J.M., Soriano R.H., Gilmour L.L., Rivers C.S., Modrusan Z., Nacu S., Guerrero S., Edgar K.A., Wallin J.J., Lamszus K., Westphal M., Heim S., James C.D., VandenBerg S.R., Costello J.F., Moorefield S., Cowdrey C.J., Prados M., Phillips H.S. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 2010, 17:362-375.
16. Cuezva J.M., Chen G., Alonso A.M., Isidoro A., Misek D.E., Hanash S.M., Beer D.G. The bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer diagnosis and prognosis. Carcinogenesis 2004, 25:1157-1163.
17. Cuezva J.M., Krajewska M., de Heredia M.L., Krajewski S., Santamaria G., Kim H., Zapata J.M., Marusawa H., Chamorro M., Reed J.C. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res. 2002, 62:6674-6681.
18. Dang C.V. Glutaminolysis: supplying carbon or nitrogen or both for cancer cells?. Cell Cycle 2010, 9:3884-3886.
19. Davis F.G., Freels S., Grutsch J., Barlas S., Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance Epidemiology, and End Results (SEER) data, 1973-1991. J. Neurosurg. 1998, 88:1-10.
20. De Bock K., Cauwenberghs S., Carmeliet P. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr. Opin. Genet. Dev. 2010, 21:73-79.
21. DeBerardinis R.J., Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2010, 29:313-324.
22. Delsite R.L., Rasmussen L.J., Rasmussen A.K., Kalen A., Goswami P.C., Singh K.K. Mitochondrial impairment is accompanied by impaired oxidative DNA repair in the nucleus. Mutagenesis 2003, 18:497-503.
23. Derr R.L., Ye X., Islas M.U., Desideri S., Saudek C.D., Grossman S.A. Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 2009, 27:1082-1086.
24. DeVivo D.C., Pagliara A.S., Prensky A.L. Ketotic hypoglycemia and the ketogenic diet. Neurology 1973, 23:640-649.
25. DeVivo D.C., Leckie M.P., Ferrendelli J.S., McDougal D.B. Chronic ketosis and cerebral metabolism. Ann. Neurol. 1978, 3:331-337.
26. Di Chiro G., Oldfield E., Wright D.C., De Michele D., Katz D.A., Patronas N.J., Doppman J.L., Larson S.M., Ito M., Kufta C.V. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am. J. Roentgenol. 1988, 150:189-197.
27. Dills W.L., Kwong E., Covey T.R., Nesheim M.C. Effects of diets deficient in glucose and glucose precursors on the growth of the Walker carcinosarcoma 256 in rats. J. Nutr. 1984, 114:2097-2106.
28. Duchowny M.S. Food for thought: the ketogenic diet and adverse effects in children. Epilepsy Curr./Am. Epilepsy Soc. 2005, 5:152-154.
29. Dwarakanath B.S. Cytotoxicity, radiosensitization, and chemosensitization of tumor cells by 2-deoxy-D-glucose in vitro. J. Cancer Res. Ther. 2009, 5(Suppl. 1):S27-S31.
30. Dwarakanath B.S., Singh D., Banerji A.K., Sarin R., Venkataramana N.K., Jalali R., Vishwanath P.N., Mohanti B.K., Tripathi R.P., Kalia V.K., Jain V. Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects. J. Cancer Res. Ther. 2009, 5(Suppl. 1):S21-S26.
31. Eloqayli H., Melo T.M., Haukvik A., Sonnewald U. [2,4-(13)C]beta-hydroxybutyrate metabolism in astrocytes and C6 glioblastoma cells. Neurochem. Res. 2011, 36:1566-1573.
32. Elstrom R.L., Bauer D.E., Buzzai M., Karnauskas R., Harris M.H., Plas D.R., Zhuang H., Cinalli R.M., Alavi A., Rudin C.M., Thompson C.B. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004, 64:3892-3899.
33. Entin-Meer M., Rephaeli A., Yang X., Nudelman A., Nudelman A., Haas-Kogan D.A. AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines. Cancer Lett. 2007, 253:205-214.
34. Ferreira L.M. Cancer metabolism: the Warburg effect today. Exp. Mol. Pathol. 2010, 89:372-380.
35. Fisher P.G., Buffler P.A. Malignant gliomas in 2005: where to GO from here?. JAMA 2005, 293:615-617.
36. Fredericks M., Ramsey R.B. 3-Oxo acid coenzyme A transferase activity in brain and tumors of the nervous system. J. Neurochem. 1978, 31:1529-1531.
37. Freeman J.M., Kossoff E.H. Ketosis and the ketogenic diet advances in treating epilepsy and other disorders. Adv. Pediatr. 2010, 57:315-329.
38. Freeman J.M., Freeman J.B., Kelly M.T. The Ketogenic Diet: A Treatment for Epilepsy 2000, Demos, New York, p. 236. third ed.
39. Freeman J.M., Kossoff E.H., Hartman A.L. The ketogenic diet: one decade later. Pediatrics 2007, 119:535-543.
40. Freeman J.M., Kossoff E.H., Freeman J.B., Kelly M.T. The Ketogenic Diet: A Treatment for Children and Others with Epilepsy 2007, Demos, New York, p. 309. Fourth ed.
41. Galluzzi L., Morselli E., Kepp O., Vitale I., Rigoni A., Vacchelli E., Michaud M., Zischka H., Castedo M., Kroemer G. Mitochondrial gateways to cancer. Mol. Aspects Med. 2010, 31:1-20.
42. Gotway M.B., Conomos P.J., Bremner R.M. Pleural metastatic disease from glioblastoma multiforme. J. Thorac. Imaging 2011, 26:W54-W58.
43. Hans P., Vanthuyne A., Dewandre P.Y., Brichant J.F., Bonhomme V. Blood glucose concentration profile after 10mg dexamethasone in non-diabetic and type 2 diabetic patients undergoing abdominal surgery. Br. J. Anaesth. 2006, 97:164-170.
44. Harik S.I., al-Mudallal A.S., LaManna J.C., Lust W.D., Levin B.E. Ketogenic diet and the brain. Ann. N. Y. Acad. Sci. 1997, 835:218-224.
45. Hawkins R.A. The blood-brain barrier and glutamate. Am. J. Clin. Nutr. 2009, 90:867S-874S.
46. Hayden E.C. Personalized cancer therapy gets closer. Nature 2009, 458:131-132.
47. Hoffman H.J., Duffner P.K. Extraneural metastases of central nervous system tumors. Cancer 1985, 56:1778-1782.
48. Huysentruyt L.C., Seyfried T.N. Perspectives on the mesenchymal origin of metastatic cancer. Cancer Metastasis Rev. 2010, 29:695-707.
49. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
50. Kallenberg K., Bock H.C., Helms G., Jung K., Wrede A., Buhk J.H., Giese A., Frahm J., Strik H., Dechent P., Knauth M. Untreated glioblastoma multiforme: increased myo-inositol and glutamine levels in the contralateral cerebral hemisphere at proton MR spectroscopy. Radiology 2009, 253:805-812.
51. Kang H.T., Hwang E.S. 2-Deoxyglucose: an anticancer and antiviral therapeutic, but not any more a low glucose mimetic. Life Sci. 2006, 78:1392-1399.
52. Kargiotis O., Geka A., Rao J.S., Kyritsis A.P. Effects of irradiation on tumor cell survival, invasion and angiogenesis. J. Neurooncol. 2010, 100:323-338.
53. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
54. Kashiwaya Y., Takeshima T., Mori N., Nakashima K., Clarke K., Veech R.L. D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:5440-5444.
55. Kashiwaya Y., Sato K., Tsuchiya N., Thomas S., Fell D.A., Veech R.L., Passonneau J.V. Control of glucose utilization in working perfused rat heart. J. Biol. Chem. 1994, 269:25502-25514.
56. Kashiwaya Y., Pawlosky R., Markis W., King M.T., Bergman C., Srivastava S., Murray A., Clarke K., Veech R.L. A ketone ester diet increased brain malonyl CoA and uncoupling protein 4 and 5 while decreasing food intake in the normal Wistar rat. J. Biol. Chem. 2010, 285:25950-25956.
57. Katayama M., Hiraide A., Sugimoto H., Yoshioka T., Sugimoto T. Effect of ketone bodies on hyperglycemia and lactic acidemia in hemorrhagic stress. Jpen 1994, 18:442-446.
58. Kiebish M.A., Han X., Cheng H., Seyfried T.N. In vitro growth environment produces lipidomic and electron transport chain abnormalities in mitochondria from non-tumorigenic astrocytes and brain tumours. ASN Neuro. 2009, 1.
59. Kiebish M.A., Han X., Cheng H., Chuang J.H., Seyfried T.N. Cardiolipin and electron transport chain abnormalities in mouse brain tumor mitochondria: lipidomic evidence supporting the Warburg theory of cancer. J. Lipid Res. 2008, 49:2545-2556.
60. Koehler P.J. Use of corticosteroids in neuro-oncology. Anticancer Drugs 1995, 6:19-33.
61. Koppenol W.H., Bounds P.L., Dang C.V. Otto Warburg's contributions to current concepts of cancer metabolism. Nat. Rev. 2011, 11:325-337.
62. Kossoff E.H. The ketogenic diet: an appropriate first-line therapy?. Expert Rev. Neurother. 2010, 10:843-845.
63. Kossoff E.H., Zupec-Kania B.A., Amark P.E., Ballaban-Gil K.R., Christina Bergqvist A.G., Blackford R., Buchhalter J.R., Caraballo R.H., Helen Cross J., Dahlin M.G., Donner E.J., Klepper J., Jehle R.S., Kim H.D., Christiana Liu Y.M., Nation J., Nordli D.R., Pfeifer H.H., Rho J.M., Stafstrom C.E., Thiele E.A., Turner Z., Wirrell E.C., Wheless J.W., Veggiotti P., Vining E.P. Optimal clinical management of children receiving the ketogenic diet: recommendations of the International Ketogenic Diet Study Group. Epilepsia 2009, 50:304-317.
64. Krex D., Klink B., Hartmann C., von Deimling A., Pietsch T., Simon M., Sabel M., Steinbach J.P., Heese O., Reifenberger G., Weller M., Schackert G. Long-term survival with glioblastoma multiforme. Brain 2007, 130:2596-2606.
65. Kulawiec M., Safina A., Desouki M.M., Still I., Matsui S.I., Bakin A., Singh K.K. Tumorigenic transformation of human breast epithelial cells induced by mitochondrial DNA depletion. Cancer Biol. Ther. 2008, 7:1732-1743.
66. Lakka S.S., Rao J.S. Antiangiogenic therapy in brain tumors. Expert Rev. Neurother. 2008, 8:1457-1473.
67. Landau B.R., Laszlo J., Stengle J., Burk D. Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-D-glucose. J. Natl. Cancer Inst. 1958, 21:485-494.
68. Lawrence T., Gilroy D.W. Chronic inflammation: a failure of resolution?. Int. J. Exp. Pathol. 2007, 88:85-94.
69. Lee W.H., Sonntag W.E., Mitschelen M., Yan H., Lee Y.W. Irradiation induces regionally specific alterations in pro-inflammatory environments in rat brain. Int. J. Radiat. Biol. 2010, 86:132-144.
70. Lennox W.G. Epilepsy and Related Disorders 1960, vol. 1. Little, Brown and Company, Boston, p. 1168.
71. Lennox W.G., Cobb S. Studies in epilepsy VIII. The clinical effect of fasting. Arch. Neurol. Psychiat. 1928, 20:771-779.
72. Lewis C., Murdoch C. Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am. J. Pathol. 2005, 167:627-635.
73. Lu J., Sharma L.K., Bai Y. Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis. Cell Res. 2009, 19:802-815.
74. Lukins M.B., Manninen P.H. Hyperglycemia in patients administered dexamethasone for craniotomy. Anesth. Analg. 2005, 100:1129-1133.
75. Lun M., Lok E., Gautam S., Wu E., Wong E.T. The natural history of extracranial metastasis from glioblastoma multiforme. J. Neurooncol. 2011.
76. Maalouf M., Rho J.M., Mattson M.P. The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Res. Rev. 2009, 59:293-315.
77. Magee B.A., Potezny N., Rofe A.M., Conyers R.A. The inhibition of malignant cell growth by ketone bodies. Aust. J. Exp. Biol. Med. Sci. 1979, 57:529-539.
78. Mahoney L.B., Denny C.A., Seyfried T.N. Caloric restriction in C57BL/6J mice mimics therapeutic fasting in humans. Lipids Health Dis. 2006, 5:13.
79. Mantis J.G., Centeno N.A., Todorova M.T., McGowan R., Seyfried T.N. Management of multifactorial idiopathic epilepsy in EL mice with caloric restriction and the ketogenic diet: role of glucose and ketone bodies. Nutr. Metab. 2004, 1:11.
80. Marsh J., Mukherjee P., Seyfried T.N. Akt-dependent proapoptotic effects of dietary restriction on late-stage management of a phosphatase and tensin homologue/tuberous sclerosis complex 2-deficient mouse astrocytoma. Clin. Cancer Res. 2008, 14:7751-7762.
81. Marsh J., Mukherjee P., Seyfried T. Drug/diet synergy for managing malignant astrocytoma in mice: 2-deoxy-D-glucose and the restricted ketogenic diet. Nutr. Metab. 2008, 5:33.
82. Mason W.P., Maestro R.D., Eisenstat D., Forsyth P., Fulton D., Laperriere N., Macdonald D., Perry J., Thiessen B. Canadian recommendations for the treatment of glioblastoma multiforme. Curr. Oncol. 2007, 14:110-117.
83. McGirt M.J., Chaichana K.L., Gathinji M., Attenello F., Than K., Ruiz A.J., Olivi A., Quinones-Hinojosa A. Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas. Neurosurgery 2008, 63:286-291. discussion 291.
84. McKenna M.C., Gruetter R., Sonnewald U., Waagepetersen H.S., Schousboe A. Energy metabolism of the brain. Basic Neurochemistry: Molecular, Cellular, and Medical Aspects 2006, 531-557. Elsevier Academic Press, New York. G.J. Siegel, R.W. Albers, S.T. Bradey, D.P. Price (Eds.).
85. Michelakis E.D., Sutendra G., Dromparis P., Webster L., Haromy A., Niven E., Maguire C., Gammer T.L., Mackey J.R., Fulton D., Abdulkarim B., McMurtry M.S., Petruk K.C. Metabolic modulation of glioblastoma with dichloroacetate. Sci. Transl. Med. 2010, 2:31ra34.
86. Monje M.L., Vogel H., Masek M., Ligon K.L., Fisher P.G., Palmer T.D. Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies. Ann. Neurol. 2007, 62:515-520.
87. Morantz R.A., Wood G.W., Foster M., Clark M., Gollahon K. Macrophages in experimental and human brain tumors. Part 2: studies of the macrophage content of human brain tumors. J. Neurosurg. 1979, 50:305-311.
88. Morris A.A. Cerebral ketone body metabolism. J. Inherit. Metab. Dis. 2005, 28:109-121.
89. Mukherjee P., Abate L.E., Seyfried T.N. Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors. Clin. Cancer Res. 2004, 10:5622-5629.
90. Mukherjee P., Zhau J.-R., Sotnikov A.V., Clinton S.K. Dietary and nutritional modulation of tumor angiogenesis. Antiangiogenic Agents in Cancer Therapy 1999, 237-261. Humana Press, Totowa, NJ. B.A. Teicher (Ed.).
91. Mukherjee P., El-Abbadi M.M., Kasperzyk J.L., Ranes M.K., Seyfried T.N. Dietary restriction reduces angiogenesis and growth in an orthotopic mouse brain tumour model. Br. J. Cancer 2002, 86:1615-1621.
92. Mukherjee P., Sotnikov A.V., Mangian H.J., Zhou J.R., Visek W.J., Clinton S.K. Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. J. Natl. Cancer Inst. 1999, 91:512-523.
93. Mulrooney T.J., Marsh J., Urits I., Seyfried T.N., Mukherjee P. Influence of caloric restriction on constitutive expression of NF-kappaB in an experimental mouse astrocytoma. PloS one 2011, 6:e18085.
94. Nebeling L.C., Miraldi F., Shurin S.B., Lerner E. Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J. Am. Coll. Nutr. 1995, 14:202-208.
95. Newsholme P. Why is L-glutamine metabolism important to cells of the immune system in health, postinjury, surgery or infection?. J. Nutr. 2001, 131:2515S-2522S. discussion 2523S-2514S.
96. Nishie A., Ono M., Shono T., Fukushi J., Otsubo M., Onoue H., Ito Y., Inamura T., Ikezaki K., Fukui M., Iwaki T., Kuwano M. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin. Cancer Res. 1999, 5:1107-1113.
97. Noch E., Khalili K. Molecular mechanisms of necrosis in glioblastoma: the role of glutamate excitotoxicity. Cancer Biol. Ther. 2009, 8:1791-1797.
98. Ohgaki H., Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci. 2009, 100:2235-2241.
99. Oleksyszyn J. The complete control of glucose level utilizing the composition of ketogenic diet with the gluconeogenesis inhibitor, the anti-diabetic drug metformin, as a potential anti-cancer therapy. Med. hypotheses 2011, 77:171-173.
100. Omar H.A., Berman-Booty L., Kulp S.K., Chen C.S. Energy restriction as an antitumor target. Future Oncol. 2010, 6:1675-1679.
101. Oudard S., Boitier E., Miccoli L., Rousset S., Dutrillaux B., Poupon M.F. Gliomas are driven by glycolysis: putative roles of hexokinase, oxidative phosphorylation and mitochondrial ultrastructure. Anticancer Res. 1997, 17:1903-1911.
102. Oudard S., Arvelo F., Miccoli L., Apiou F., Dutrillaux A.M., Poisson M., Dutrillaux B., Poupon M.F. High glycolysis in gliomas despite low hexokinase transcription and activity correlated to chromosome 10 loss. Br. J. Cancer 1996, 74:839-845.
103. Oudard S., Poirson F., Miccoli L., Bourgeois Y., Vassault A., Poisson M., Magdelenat H., Dutrillaux B., Poupon M.F. Mitochondria-bound hexokinase as target for therapy of malignant gliomas. Int. J. Cancer 1995, 62:216-222.
104. Owen O.E., Morgan A.P., Kemp H.G., Sullivan J.M., Herrera M.G., Cahill G.F. Brain metabolism during fasting. J. Clin. Investig. 1967, 46:1589-1595.
105. Pedersen P.L. Tumor mitochondria and the bioenergetics of cancer cells. Prog. Exp. Tumor Res. 1978, 22:190-274.
106. Pelicano H., Martin D.S., Xu R.H., Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006, 25:4633-4646.
107. Phillips J.P., Eremin O., Anderson J.R. Lymphoreticular cells in human brain tumours and in normal brain. Br. J. Cancer 1982, 45:61-69.
108. Phoenix K.N., Vumbaca F., Fox M.M., Evans R., Claffey K.P. Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy. Breast Cancer Res. Treat. 2010, 123:333-344.
109. Portnow J., Suleman S., Grossman S.A., Eller S., Carson K. A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intracerebral 9L gliosarcomas. Neuro-oncology 2002, 4:22-25.
110. Prestegarden L., Svendsen A., Wang J., Sleire L., Skaftnesmo K.O., Bjerkvig R., Yan T., Askland L., Persson A., Sakariassen P.O., Enger P.O. Glioma cell populations grouped by different cell type markers drive brain tumor growth. Cancer Res. 2010, 70:4274-4279.
111. Puchowicz M.A., Xu K., Sun X., Ivy A., Emancipator D., LaManna J.C. Diet-induced ketosis increases capillary density without altered blood flow in rat brain. Am. J. Physiol. Endocrinol. Metab. 2007, 292:E1607-E1615.
112. Puchowicz M.A., Emancipator D.S., Xu K., Magness D.L., Ndubuizu O.I., Lust W.D., LaManna J.C. Adaptation to chronic hypoxia during diet-induced ketosis. Adv. Exp. Med. Biol. 2005, 566:51-57.
113. Raffaghello L., Lee C., Safdie F.M., Wei M., Madia F., Bianchi G., Longo V.D. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:8215-8220.
114. Ramanathan A., Wang C., Schreiber S.L. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:5992-5997.
115. Rasmussen A.K., Chatterjee A., Rasmussen L.J., Singh K.K. Mitochondria-mediated nuclear mutator phenotype in Saccharomyces cerevisiae. Nucleic Acids Res. 2003, 31:3909-3917.
116. Renner C., Asperger A., Seyffarth A., Meixensberger J., Gebhardt R., Gaunitz F. Carnosine inhibits ATP production in cells from malignant glioma. Neurol. Res. 2010, 32:101-105.
117. Roskelley R.C., Mayer N., Horwitt B.N., Salter W.T. Studies in cancer. Vii. Enzyme deficiency in human and experimental cancer. J. Clin. Investig. 1943, 22:743-751.
118. Rous P. The influence of diet on transplanted and spontaneous mouse tumors. J. Exp. Med. 1914, 20:433-451.
119. Safdie F.M., Dorff T., Quinn D., Fontana L., Wei M., Lee C., Cohen P., Longo V.D. Fasting and cancer treatment in humans: a case series report. Aging (Albany NY) 2009, 1:988-1007.
120. Scherer H.J. A critical review: the pathology of cerebral gliomas. J. Neurol. Neuropsychiat. 1940, 3:147-177.
121. Schwimmer C., Lefebvre-Legendre L., Rak M., Devin A., Slonimski P.P., di Rago J.P., Rigoulet M. Increasing mitochondrial substrate-level phosphorylation can rescue respiratory growth of an ATP synthase-deficient yeast. J. Biol. Chem. 2005, 280:30751-30759.
122. Seyfried T.N. Perspectives on brain tumor formation involving macrophages, glia, and neural stem cells. Perspect. Biol. Med. 2001, 44:263-282.
123. Seyfried T.N. Mitochondrial glutamine fermentation enhances ATP synthesisin murine glioblastoma cells. Proceedings of the 102 nd Annual Meeting of the Amer. Assoc. Cancer Res. 2011.
124. Seyfried T.N., Mukherjee P. Targeting energy metabolism in brain cancer: review and hypothesis. Nutr. Metab. 2005, 2:30.
125. Seyfried T.N., Mukherjee P. Anti-angiogenic and pro-apoptotic effects of dietary restriction in experimental brain cancer: role of glucose and ketone bodies. Integration/Interaction of Oncologic Growth 2005, Vol. 15:259-270. Kluwer Academic, New York. 2nd ed.
126. Seyfried T.N., Shelton L.M. Cancer as a metabolic disease. Nutr. Metab. 2010, 7:7.
127. Seyfried T.N., Greene A.E., Todorova M.M. Caloric restriction and epilepsy: historical perspectives, relationship to the ketogenic diet, and analysis in epileptic EL mice. Epilepsy and the Ketogenic Diet 2004, 247-264. Humana Press Inc., Totowa, NJ. C.E. Stafstrom, J.M. Rho (Eds.).
128. Seyfried T.N., Shelton L.M., Mukherjee P. Does the existing standard of care increase glioblastoma energy metabolism?. Lancet Oncol. 2010, 11:811-813.
129. Seyfried T.N., Kiebish M., Mukherjee P., Marsh J. Targeting energy metabolism in brain cancer with calorically restricted ketogenic diets. Epilepsia 2008, 49(Suppl. 8):114-116.
130. Seyfried T.N., Sanderson T.M., El-Abbadi M.M., McGowan R., Mukherjee P. Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. Br. J. Cancer 2003, 89:1375-1382.
131. Seyfried T.N., Kiebish M.A., Marsh J., Shelton L.M., Huysentruyt L.C., Mukherjee P. Metabolic management of brain cancer. Biochim. Biophys. Acta 2010, 1807:577-594.
132. Shelton H.M. Fasting for Renewal of Life 1974, Amer. Nat. Hygene Soc., Inc., Tampa, FL, p. 314.
133. Shelton L.M., Huysentruyt L.C., Seyfried T. Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model. Int. J. Cancer 2010.
134. Shelton L.M., Huysentruyt L.C., Mukherjee P., Seyfried T. Calorie restriction as an anti-invasive therapy for malignant brain cancer in the VM mouse. ASN Neuro. 2010, 2:e00038.
135. Shelton L.M., Strelko C.L., Roberts M.F., Seyfried N. Krebs cycle substrate-level phosphorylation drives metastatic cancer cells. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research 2010.
136. Shelton L.M., Mukherjee P., Huysentruyt L.C., Urits I., Rosenberg J.A., Seyfried T. A novel pre-clinical in vivo mouse model for malignant brain tumor growth and invasion. J. Neurooncol. 2010, 99:165-176.
137. Shinonaga M., Chang C.C., Suzuki N., Sato M., Kuwabara T. Immunohistological evaluation of macrophage infiltrates in brain tumors. Correlation with peritumoral edema. J. Neurosurg. 1988, 68:259-265.
138. Singh D. Dose esclation studies in patients of glioblastoma. Applications of 2-Deoxy-D-Glucose in Management of Cancer 2006.
139. Singh D., Banerji A.K., Dwarakanath B.S., Tripathi R.P., Gupta J.P., Mathew T.L., Ravindranath T., Jain V. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther. Onkol. 2005, 181:507-514.
140. Skinner R., Trujillo A., Ma X., Beierle E.A. Ketone bodies inhibit the viability of human neuroblastoma cells. J. Pediatr. Surg. 2009, 44:212-216. discussion 216.
141. Smiraglia D.J., Kulawiec M., Bistulfi G.L., Gupta S.G., Singh K.K. A novel role for mitochondria in regulating epigenetic modification in the nucleus. Cancer Biol. Ther. 2008, 7:1182-1190.
142. Souhami L., Seiferheld W., Brachman D., Podgorsak E.B., Werner-Wasik M., Lustig R., Schultz C.J., Sause W., Okunieff P., Buckner J., Zamorano L., Mehta M.P., Curran W.J. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int. J. Radiat. Oncol. Biol. Phys. 2004, 60:853-860.
143. Spence A.M., Muzi M., Graham M.M., O'Sullivan F., Krohn K.A., Link J.M., Lewellen T.K., Lewellen B., Freeman S.D., Berger M.S., Ojemann G.A. Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: analysis of the FDG lumped constant. J. Nucl. Med. 1998, 39:440-448.
144. Stafford P., Abdelwahab M.G., Kim do Y., Preul M.C., Rho J.M., Scheck A.C. The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr. Metab. 2010, 7:74.
145. Staw B.M., Ross J. Understanding behavior in escalation situations. Science 1989, 246:216-220.
146. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K., Hau P., Brandes A.A., Gijtenbeek J., Marosi C., Vecht C.J., Mokhtari K., Wesseling P., Villa S., Eisenhauer E., Gorlia T., Weller M., Lacombe D., Cairncross J.G., Mirimanoff R.O. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10:459-466.
147. Szent-Gyorgyi A. The living state and cancer. Proc. Natl. Acad. Sci. U.S.A. 1977, 74:2844-2847.
148. Szerlip N., Rutter C., Ram N., Yovino S., Kwok Y., Maggio W., Regine W.F. Factors impacting volumetric white matter changes following whole brain radiation therapy. J. Neurooncol. 2011, 103:111-119.
149. Taha M., Ahmad A., Wharton S., Jellinek D. Extra-cranial metastasis of glioblastoma multiforme presenting as acute parotitis. Br. J. Neurosurg. 2005, 19:348-351.
150. Takano T., Lin J.H., Arcuino G., Gao Q., Yang J., Nedergaard M. Glutamate release promotes growth of malignant gliomas. Nat. Med. 2001, 7:1010-1015.
151. Talacchi A., Turazzi S., Locatelli F., Sala F., Beltramello A., Alessandrini F., Manganotti P., Lanteri P., Gambin R., Ganau M., Tramontano V., Santini B., Gerosa M. Surgical treatment of high-grade gliomas in motor areas. The impact of different supportive technologies: a 171-patient series. J. Neurooncol. 2010, 100:417-426.
152. Thompson H.J., McGinley J.N., Spoelstra N.S., Jiang W., Zhu Z., Wolfe P. Effect of dietary energy restriction on vascular density during mammary carcinogenesis. Cancer Res. 2004, 64:5643-5650.
153. Tisdale M.J., Brennan R.A. Loss of acetoacetate coenzyme A transferase activity in tumours of peripheral tissues. Br. J. Cancer 1983, 47:293-297.
154. Tso C.L., Shintaku P., Chen J., Liu Q., Liu J., Chen Z., Yoshimoto K., Mischel P.S., Cloughesy T.F., Liau L.M., Nelson S.F. Primary glioblastomas express mesenchymal stem-like properties. Mol. Cancer Res. 2006, 4:607-619.
155. VanItallie T.B., Nufert T.H. Ketones: metabolism's ugly duckling. Nutr. Rev. 2003, 61:327-341.
156. Veatch J.R., McMurray M.A., Nelson Z.W., Gottschling D.E. Mitochondrial dysfunction leads to nuclear genome instability via an iron-sulfur cluster defect. Cell 2009, 137:1247-1258.
157. Veech R.L., Chance B., Kashiwaya Y., Lardy H.A., Cahill G.F. Ketone bodies, potential therapeutic uses. IUBMB Life 2001, 51:241-247.
158. Verbeek M.M., Otte-Holler I., Wesseling P., Ruiter D.J., de Waal R.M. Induction of alpha-smooth muscle actin expression in cultured human brain pericytes by transforming growth factor-beta 1. Am. J. Pathol. 1994, 144:372-382.
159. Villalobo A., Lehninger A.L. The proton stoichiometry of electron transport in Ehrlich ascites tumor mitochondria. J. Biol. Chem. 1979, 254:4352-4358.
160. Wang J.B., Erickson J.W., Fuji R., Ramachandran S., Gao P., Dinavahi R., Wilson K.F., Ambrosio A.L., Dias S.M., Dang C.V., Cerione R.A. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010, 18:207-219.
161. Warburg O. The Metabolism of Tumours 1931, Richard R. Smith, New York, p. 327.
162. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
163. Warburg O. On the respiratory impairment in cancer cells. Science 1956, 124:269-270.
164. Wartenberg M., Richter M., Datchev A., Gunther S., Milosevic N., Bekhite M.M., Figulla H.R., Aran J.M., Petriz J., Sauer H. Glycolytic pyruvate regulates P-glycoprotein expression in multicellular tumor spheroids via modulation of the intracellular redox state. J. Cell. Biochem. 2010, 109:434-446.
165. Wise D.R., DeBerardinis R.J., Mancuso A., Sayed N., Zhang X.Y., Pfeiffer H.K., Nissim I., Daikhin E., Yudkoff M., McMahon S.B., Thompson C.B. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:18782-18787.
166. Yang C., Sudderth J., Dang T., Bachoo R.G., McDonald J.G., Deberardinis R.J. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res. 2009, 69:7986-7993.
167. Yang D., Wang M.T., Tang Y., Chen Y., Jiang H., Jones T.T., Rao K., Brewer G.J., Singh K.K., Nie D. Impairment of mitochondrial respiration in mouse fibroblasts by oncogenic H-RAS(Q61L). Cancer Biol. Ther. 2010, 9:122-133.
168. Yang I., Liau L.M. American association for cancer research genetics and biology of brain cancers 2009, December 13-15, 2009, San Diego CA. J. Neurooncol. 2010, 99:297-306.
169. Yudkoff M., Daikhin Y., Melo T.M., Nissim I., Sonnewald U., Nissim I. The ketogenic diet and brain metabolism of amino acids: relationship to the anticonvulsant effect. Annu. Rev. Nutr. 2007, 27:415-430.
170. Zagzag D., Esencay M., Mendez O., Yee H., Smirnova I., Huang Y., Chiriboga L., Lukyanov E., Liu M., Newcomb E.W. Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures. Am. J. Pathol. 2008, 173:545-560.
171. Zhen L., Yufeng C., Zhenyu S., Lei X. Multiple extracranial metastases from secondary glioblastoma multiforme: a case report and review of the literature. J. Neurooncol. 2010, 97:451-457.
172. Zhou W., Mukherjee P., Kiebish M.A., Markis W.T., Mantis J.G., Seyfried T.N. The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Nutr. Metab. 2007, 4:5.
173. Zhu Z., Jiang W., McGinley J.N., Thompson H.J. 2-Deoxyglucose as an energy restriction mimetic agent: effects on mammary carcinogenesis and on mammary tumor cell growth in vitro. Cancer Res. 2005, 65:7023-7030.
174. Zhuang W., Qin Z., Liang Z. The role of autophagy in sensitizing malignant glioma cells to radiation therapy. Acta Biochim. Biophys. Sin. (Shanghai) 2009, 41:341-351.
175. Zuccoli G., Marcello N., Pisanello A., Servadei F., Vaccaro S., Mukherjee P., Seyfried T.N. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: case report. Nutr. Metab. 2010, 7:33.